Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy LN Tumey, M Charati, T He, E Sousa, D Ma, X Han, T Clark, J Casavant, ... Bioconjugate chemistry 25 (10), 1871-1880, 2014 | 206 | 2014 |
Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery DD Fang, YJ Kim, CN Lee, S Aggarwal, K McKinnon, D Mesmer, J Norton, ... British journal of cancer 102 (8), 1265-1275, 2010 | 178 | 2010 |
Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients GR Nicol, M Han, J Kim, CE Birse, E Brand, A Nguyen, M Mesri, ... Molecular & Cellular Proteomics 7 (10), 1974-1982, 2008 | 142 | 2008 |
GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates DM Breen, H Kim, D Bennett, RA Calle, S Collins, RM Esquejo, T He, ... Cell metabolism 32 (6), 938-950. e6, 2020 | 109 | 2020 |
Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer AR Root, W Cao, B Li, P LaPan, C Meade, J Sanford, M Jin, C O’Sullivan, ... Antibodies 5 (1), 6, 2016 | 93 | 2016 |
Lung disease targets and uses thereof B Domon, E Joseloff, A Li, T He US Patent 7,807,392, 2010 | 68 | 2010 |
Breast disease targets and uses thereof J Heidbrink, S Ruben, CE Birse, T He US Patent 7,842,467, 2010 | 67 | 2010 |
Quantitation of phosphopeptides using affinity chromatography and stable isotope labeling T He, K Alving, B Feild, J Norton, EG Joseloff, SD Patterson, B Domon Journal of the American Society for Mass Spectrometry 15 (3), 363-373, 2004 | 63 | 2004 |
Kidney disease targets and uses thereof E Joseloff, S Ruben, T He, YJ Kim US Patent 7,608,413, 2009 | 58 | 2009 |
Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium CE Birse, RJ Lagier, W FitzHugh, HI Pass, WN Rom, ES Edell, ... Clinical proteomics 12, 1-12, 2015 | 55 | 2015 |
Integrating titania enrichment, iTRAQ labeling, and Orbitrap CID‐HCD for global identification and quantitative analysis of phosphopeptides J Wu, P Warren, Q Shakey, E Sousa, A Hill, TE Ryan, T He Proteomics 10 (11), 2224-2234, 2010 | 48 | 2010 |
Kidney disease targets and uses thereof E Joseloff, S Ruben, T He, Y Kim US Patent App. 13/183,696, 2012 | 43 | 2012 |
Reproducibility Assessment of Relative Quantitation Strategies for LC− MS Based Proteomics YJ Kim, P Zhan, B Feild, SM Ruben, T He Analytical chemistry 79 (15), 5651-5658, 2007 | 42 | 2007 |
Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues M Mesri, C Birse, J Heidbrink, K McKinnon, E Brand, CL Bermingham, ... PLoS One 8 (11), e78885, 2013 | 41 | 2013 |
Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer S Aggarwal, T He, W FitzHugh, K Rosenthal, B Feild, J Heidbrink, ... Gynecologic oncology 115 (3), 430-437, 2009 | 39 | 2009 |
Lung disease targets and uses thereof E Joseloff, A Li, T He, S Ruben US Patent App. 12/400,212, 2009 | 34 | 2009 |
Detection of CXADR protein for diagnosis of kidney cancer E Joseloff, S Ruben, T He, Y Kim US Patent 7,998,689, 2011 | 33 | 2011 |
Glyco-engineered long acting FGF21 variant with optimal pharmaceutical and pharmacokinetic properties to enable weekly to twice monthly subcutaneous dosing Y Weng, T Ishino, A Sievers, S Talukdar, JR Chabot, A Tam, W Duan, ... Scientific Reports 8 (1), 4241, 2018 | 26 | 2018 |
Colon disease targets and uses thereof Y Kim, T He, S Ruben US Patent 7,842,466, 2010 | 26 | 2010 |
Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions X Zhong, E Kieras, E Sousa, A D'Antona, JC Baber, T He, J Desharnais, ... Journal of Biological Chemistry 288 (2), 1409-1419, 2013 | 22 | 2013 |